Tianjin Kingyork-Pharmaceuticals Co., Ltd.
Established in November 2010, Tianjin Kingyork-Pharmaceuticals Co., Ltd. is a controlled subsidiary of Tianjin Tianyao Pharmaceutical Co., Ltd. subordinate to Tianjin KingYork Group Co., Ltd. Its registered capital is RMB 600 million and its total asset value is RMB 1.45 billion. Since 2010, KingYork Group has carried out a reconstruction project of KingYork Pharmaceutical Park with KingYork Pharmaceutical as the main implementer, and has invested RMB 800 million to upgrade the Pharmaceutical Park, which has been gradually put into operation since 2013. As a National High-tech Enterprise, Tianjin Science and Technology Leader, Tianjin Science and Technology Little Giant Enterprise, and Tianjin Scientific and Technological Enterprise, KingYork Pharmaceutical is committed to becoming a leading corticosteroid drug R&D and production base in the world.
